Colorectal Adenocarcinoma

This case demonstrates that osimertinib can achieve an early, deep, and sustainable response in patients with a rare G719A/L861Q co-mutation. Prospective evidence is necessary for rare EGFR subtypes.

IL-1β ranged from 1341 to 3371 pg/mL, IL-6 from 169 to 280 pg/mL, IL-10 from 220 to 859 pg/mL, and TNF-α from 126 to 263 pg/mL across the tested conditions. This study is a preliminary investigation into the potential biotechnological applications of CMβ-gluM16, indicating its promise for further research.

Metabolomic profiling using HPLC and GC-MS revealed strain-specific signatures dominated by organic acids, volatile compounds, and fatty acids associated with oxidative, inflammatory, and apoptotic modulation. Collectively, these findings demonstrate that freeze-dried CFS exert anticancer effects through coordinated transcriptomic-independent, proteomic, and metabolomic mechanisms, highlighting their potential as multifunctional postbiotic candidates for colorectal cancer intervention.

P=N/A, N=50, Recruiting, Centre Paul Strauss | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026

Our results show that embedding choice has a substantial and consistent impact on OS prediction accuracy, robustness, and interpretability across cancer types, with domain-specific and foundation models outperforming conventional convolutional baselines. These findings provide evidence-based practical guidelines for designing robust and generalizable WSI-based survival prediction pipelines in computational pathology.

The patient subsequently underwent neoadjuvant chemoradiotherapy (50.4 Gy in 28 fractions) combined with two cycles of capecitabine plus oxaliplatin (CapeOx) and tislelizumab, achieving significant tumor regression (yT2N0M0). LS-associated rectal cancer during pregnancy requires individualized, multidisciplinary management. Medical termination followed by neoadjuvant immunochemoradiotherapy can optimize maternal outcomes while minimizing fetal and genetic risks.

YORC presents more often with symptoms and advanced disease (M+, N+, EMVI+), yet short-term survival in non-metastatic patients tended to parallel that of older individuals. These findings underscore the need for earlier diagnosis, tailored management, and increased clinical awareness.

Our findings indicate that CTLA-4 and CD28 are upregulated in patients with colorectal polyps and exhibit a positive correlation in expression. The regulatory network analysis highlights KCNQ1OT1 as a potential upstream modulator of these genes via miRNA-mediated mechanisms. Moreover, the strong association between CTLA-4 and CD28 expression and immune cell infiltration underscores their potential role in immune dysregulation during the early stages of colorectal tumorigenesis. Collectively, these findings suggest that CTLA-4 and CD28 may contribute to polyp progression through modulation of the immune microenvironment.

P2, N=86, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Sep 2026 --> Feb 2026

Its effects may involve cell-type-specific immune regulation and partial mediation through metabolic reprogramming. While the primary causal inference of this study focused on COAD, complementary single-cell and spatial transcriptomic findings from broader CRC datasets provided supportive expression-level evidence consistent with these associations.

Rescue experiments demonstrated that miR-375's regulatory role in COAD malignant progression was partly dependent on SLC6A6. Our research elucidates a cuproptosis-related ceRNA regulatory network and offers novel potential targets for COAD diagnosis and therapy of COAD.

The risk model based on ferroptosis-related lncRNAs showed favorable prognostic predictive performance for COAD and might provide a potential reference for clinical personalized adjuvant therapy.